SYF46d35c8704914d938f11e28912871686Registry ID: 2024-513997-23-00|UnknownPhase 2Results
Loading search results
interventional
N/A
1 country
1
To compare the uptake of 68GaNOTA-Anti-HER2 VHH1 in brain metastasis lesions from HER2-positive and HER2-negative patients
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 18, 2024
Actual (reported)The tumor targeting potential in brain metastasis will be visually scored as positive or negative by an experienced nuclear medicine physician, unaware of the HER2-status
The tumor targeting potential in brain metastasis will be assessed quantitatively using Standard Uptake Values (SUV) by an experienced nuclear medicine physician, unaware of the HER2-status.
If available, uptake will be evaluated during and after treatment and compared to baseline values. Results will be compared to information of patient's disease course.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
UZ Brussel
Jette, 1090, Belgium
Prof. Dr. Tony Lahoutte
First Submitted
July 18, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.